.png){kind=icon}
.png){kind=icon}
Return
Development and Validation of an Interpretable Model Integrating Radiomics and Clinical Data for Predicting 70-gene Signature Risk in Breast Cancer: A Multicenter Study
.png){kind=icon}
PRE
AI
Y
T
Z
H
L
Q
DOI：10.1016/j.acra.2026.06.003.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The 70-gene signature (MammaPrint) guides risk assessment and treatment in the hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) early breast cancer but is limited by cost and laboratory requirements. This study aimed to develop and externally validate an interpretable MRI radiomics-clinical machine learning model to predict 70-gene signature status in patients with HR+/HER2– early-stage breast cancer.
Journal
IF:
3.9
Papers:
8.6K
Citations:
1.0W
Organization
Cited Papers